Aequus Pharmaceuticals Inc. (V:AQS)

Business Focus: Pharmaceuticals (NEC)

Get the company report for the most recent outlook updated daily

Apr 29, 2024 08:30 pm ET

Aequus Provides General Update and Fiscal 2023 Financial Results

VANCOUVER – TheNewswire - April 29, 2024 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company focused on bringing healthcare solutions to Canadians through licensing and partnerships, today reports financial results for the year ended December 31, 2023 (“Fiscal 2023”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency.

Nov 29, 2023 06:05 pm ET

Aequus Reports Third Quarter 2023 Financial Highlights and General Update

Vancouver, BC - TheNewswire - November 29, 2023 - Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTC:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reports financial results for the quarter ended September 30, 2023 (“Third Quarter 2023”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency.

Oct 20, 2023 02:53 pm ET

Aequus Announces New Financing

Vancouver, BC - TheNewswire - October 20, 2023 - Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTC: AQSZF) (“Aequus” or the “Company”), announces today it has increased its debt by $1,000,000 to support operating costs and the new sales of Zimed® PF. Mr. Doug Janzen, Chairman and Chief Executive Officer of the Company, has agreed to provide financing to Aequus by way of advanced funds on the same general conditions as previous advances, which is on demand with an interest rate of five percent (5%).

Oct 06, 2023 07:45 pm ET

Aequus Announces New Financing and Provides Launch Update of Zimed Preservative Free (Bimatoprost 0.03%)

VANCOUVER, BC – TheNewswire - October 6, 2023 - Aequus Pharmaceuticals Inc. (TSXV:AQS), (OTC:AQSZF) (“Aequus” or the “Company”), announces today it has increased its debt by $270,000 to support operating costs andthe new sales of Zimed® PF. Mr. Doug Janzen, Chairman and Chief Executive Officer of the Company, has agreed to provide financing to Aequus by way of an unsecured demand loan of C$270,000 (the “Loan”). The Loan bears interest at an annual rate of two and a half percent (2.5%) to be calculated and repaid monthly and is repayable on demand.

Aug 29, 2023 09:53 pm ET

Aequus Reports Second Quarter 2023 Financial Highlights and General Update

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reports financial results for the quarter...

Aug 24, 2023 08:00 am ET

Aequus Announces Zimed PF Now Available in Canada

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) (“Aequus” or the “Company”), a specialty pharmaceutical company announced today, we are thrilled to announce the launch of Zimed® PF, the first preservative-free multi-dose Bimatoprost for...

Aug 22, 2023 08:00 am ET

Aequus Announces Zimed PF Website Launch

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) (“Aequus” or the “Company”), a specialty pharmaceutical company, are thrilled to announce the launch of our user friendly education website for patients and professionals. With a focus on...

Aug 18, 2023 08:00 am ET

Aequus Pharmaceutical Canada Announces a Pause in Sales of Evolve Intensive Eyedrops and Gel in Canada

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) (“Aequus” or the “Company”), a specialty pharmaceutical company announces the pause of sales of its Evolve Intensive eyedrop and Intensive gel products in Canada. The manufacturer,...

Jul 06, 2023 07:21 pm ET

Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%)

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announces today it has increased its debt by $400,000 to support the launch of Zimed® PF. Mr. Doug Janzen, Chairman and Chief Executive Officer of the Company, has...

May 30, 2023 08:23 pm ET

Aequus Provides General Update and First Quarter 2023 Financial Highlights

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the quarter...

May 01, 2023 09:12 pm ET

Aequus Provides General Update and Fiscal 2022 Financial Results

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company focused on bringing healthcare solutions to Canadians through licensing and partnerships, today reports financial results for the...

Apr 19, 2023 04:05 pm ET

Aequus Grants Stock Options

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announces that it has granted incentive stock options (the “Options”) to certain directors, officers, employees, and consultants of the Company to purchase up to an...

Apr 05, 2023 08:30 am ET

Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%) and Board Update

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announced today it has entered into a loan agreement to raise $500,000 to support the launch of Zimed® PF. Mr. Doug Janzen, Chairman and Chief Executive Officer of...

Dec 20, 2022 08:30 am ET

Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), is pleased to announce that Health Canada has approved Zimed® PF (Bimatoprost 0.03%) for the reduction of elevated intraocular pressure (IOP) in patients with...

Nov 29, 2022 08:21 pm ET

Aequus Reports Third Quarter 2022 Financial Highlights

Nov 29, 2022 08:00 am ET

Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed® PF (Preservative Free)

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announced today that it has agreed to end its promotional service agreement with Sandoz Canada Inc. (“Sandoz”) on Tacrolimus Immediate Release...

Aug 29, 2022 07:49 pm ET

Aequus Reports Second Quarter 2022 Financial Highlights and General Update

Jul 23, 2022 12:09 am ET

Press Release for Early Warning Report Regarding Aequus Pharmaceuticals Inc.

Doug Janzen, of 2820 – 200 Granville St., Vancouver, BC, V6C 1S4, today announced that on Tuesday, July 19, 2022, he acquired ownership (the “Acquisition”) of 100,000 common shares (“Common Shares”) in the capital of Aequus Pharmaceuticals Inc....

Jul 13, 2022 04:11 pm ET

IIROC Trading Resumption - AQS

VANCOUVER, BC, July 13, 2022 /CNW/ - Trading resumes in:

Jul 13, 2022 04:00 pm ET

Aequus Resumes Trading on TSX Venture Exchange

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) announces that further to our news release dated July 6, 2022, we will resume trading on the TSX Venture exchange tomorrow, July 14, 2022. Doug Janzen noted that “We will be taking steps to...

Jul 06, 2022 06:23 pm ET

Aequus Signs Exclusive Distribution Agreement with SCOPE Ophthalmics for Canadian Distribution Rights of Dry Eye Products

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce the signing of an exclusive distribution agreement with SCOPE Ophthalmics. (“SCOPE”), an Irish based eyecare company with a focus on...

Jul 01, 2022 05:51 pm ET

Aequus Provides General Update and Reports Record 2021 Financial Results

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a sales force that currently markets third party or exclusively licensed products for which the Company receives revenues...

Jun 13, 2022 09:00 am ET

Aequus Provides Update on Delay in Filing Annual Financial Statements

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that further to its news release on May 6, 2022 and May 26, 2022, the filing of its audited annual financial statements for the fiscal year ended December...

May 27, 2022 08:00 am ET

Aequus Provides Update on Delay in Filing Annual Financial Statements

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that further to its news release on May 6, 2022, the filing of its audited annual financial statements for the fiscal year ended December 31, 2021 and its...

May 10, 2022 08:13 am ET

IIROC Trading Halt - AQS

VANCOUVER, BC, May 10, 2022 /CNW/ - The following issues have been halted by IIROC:

May 06, 2022 07:30 pm ET

Aequus Provides Update on Delay in Filing Annual Financial Statements

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that further to its news release on May 2, 2022, the filing of its audited annual financial statements for the fiscal year ended December 31, 2021 and its...

May 02, 2022 08:30 pm ET

Aequus Announces Delay in Filing Annual Financial Statements

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that the filing of its audited annual financial statements for the fiscal year ended December 31, 2021 and its management’s discussion and analysis...

May 02, 2022 08:58 am ET

IIROC Trading Halt - AQS.DB

VANCOUVER, BC, May 2, 2022 /CNW/ - The following issues have been halted by IIROC:

May 02, 2022 08:00 am ET

Aequus Announces Short Term Loan

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that it has entered into an agreement with Mr. Doug Janzen, Chairman and Chief Executive Officer of the Company, pursuant to which Mr. Janzen will provide...

Apr 22, 2022 04:30 pm ET

Aequus Announces Director Resignation

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announces that Mr. Jason Flowerday has resigned from the Aequus Board of...

Jan 24, 2022 08:00 am ET

Aequus Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announced today that it has agreed to an extension of terms for its promotional service agreement with Sandoz on Tacrolimus immediate-release (“Tacrolimus IR”) to...

Jan 11, 2022 09:00 am ET

Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce a 1-year extension of terms...

Jan 06, 2022 09:00 am ET

Aequus Announces Canadian Filing of NDS for Preservative-Free Glaucoma Medication

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) (“Aequus” or the “Company”), a specialty pharmaceutical company announced today that it has submitted a New Drug Submission (NDS) application to Health Canada for preservative-free...

Nov 03, 2021 05:00 am ET

Aequus Reports Third Quarter 2021 Financial Highlights

Aug 30, 2021 08:00 am ET

Aequus Reports Second Quarter 2021 Financial Highlights

Aug 25, 2021 08:00 am ET

Aequus Strengthens Clinical Experience in Stargardt Disease with Pediatric Ophthalmology Expertise

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”) a speciality pharmaceutical company, is pleased to announce that Dr. Robert K. Koenekoop MD, MSc, PhD, FRCS(C), FARVO has joined as a medical and clinical consultant to Aequus on...

Aug 17, 2021 08:00 am ET

Aequus and reVision to Collaborate on Stargardt Disease Program

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”) and reVision Therapeutics, Inc. (“reVision”) announce a collaboration on the development of a therapy for Stargardt disease. Aequus is a specialty pharmaceutical company with...

Aug 17, 2021 08:00 am ET

Aequus and reVision to Collaborate on Stargardt Disease Program

VANCOUVER, BC and RIDGEWOOD, N.J., Aug. 17, 2021 /PRNewswire/ -- Aequus Pharmaceuticals Inc. (TSX-V: AQS) (OTCQB: AQSZF) ("Aequus") and reVision Therapeutics, Inc. ("reVision") announce a collaboration on the development of a therapy for Stargardt disease. Aequus is a specialty pharmaceutical company with multiple commercial eye care products and reVision is a privately-held, biopharmaceutical company focused on the development and commercialization of innovative therapies for rare ocular diseases. The agreement allows Aequus the option to acquire North American commercial rights to REV-0100

Jun 09, 2021 08:00 am ET

Aequus Provides Commercial Update

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that the current commercial...

May 31, 2021 05:00 am ET

Aequus Provides General Update and First Quarter 2021 Financial Highlights

Apr 23, 2021 05:00 am ET

Aequus Provides General Update and Reports Record 2020 Financial Results

Apr 19, 2021 08:00 am ET

Aequus to Present at the 2021 Bloom Burton & Co. Healthcare Investor Conference

Aequus Pharmaceuticals Inc. (TSX: AQS, OTCQB: AQSZF), a Canadian based specialty pharmaceutical company, will be presenting at the 2021 Bloom Burton & Co. Healthcare Investor Conference. Chairman and CEO, Doug Janzen, is scheduled to present at the...

Apr 06, 2021 08:00 am ET

Aequus Provides update on Warrant Acceleration

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), a specialty pharmaceutical company with a focus on advancing and promoting differentiated products is pleased to announce that further to its news release from March 2, 2021, shareholders...

Mar 02, 2021 09:57 pm ET

Aequus Announces Notice of Warrant Acceleration

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products is pleased to announce that it has elected to exercise its right under the terms...

Mar 01, 2021 08:00 am ET

Aequus Launches Evolve Eyedrops to Eye Care Professionals in Canada

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a Canadian specialty pharmaceutical company announces the commercial availability of EvolveTM preservative free lubricating eye drops for dry eye care. These...

Feb 26, 2021 08:45 pm ET

Aequus Closes $1 Million Financing

Feb 12, 2021 08:00 am ET

Aequus Announces Marc Lustig Joining Board of Directors and Making Direct Equity Investment into the Company

Dec 23, 2020 04:32 pm ET

Aequus Pharma 2021 Outlook and Holiday Wishes

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today a message from the CEO and Chairman of Aequus, Doug Janzen....

Dec 08, 2020 09:13 pm ET

Aequus Announces Issuance of Stock Options

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today a grant of 1,445,000 stock options...

Nov 30, 2020 09:00 am ET

Aequus Provides Third Quarter 2020 Financial Highlights

Nov 12, 2020 08:30 pm ET

Aequus Announces Anne Stevens’ Leadership Change

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products announces Ms Anne Stevens is stepping down from her role as Chief Operating...

Oct 29, 2020 08:00 am ET

Aequus Receives Approval for New ‘Evolve - Daily Intensive’ Lubricating Eye Drops in Canada

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company announced today that together with its partner, Medicom Healthcare Ltd. (“Medicom”), has been issued a new Medical Device License...

Oct 19, 2020 08:00 am ET

Aequus Receives Approval for New ‘Evolve - Intensive Gel’ Lubricating Eye Drops in Canada

Oct 16, 2020 08:00 am ET

Aequus Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announced today that it has agreed to an extension of terms for its promotional service agreement with Sandoz Canada Inc. (“Sandoz”) on tacrolimus immediate-release...

Sep 22, 2020 09:37 am ET

Aequus Announces Expansion of Medicom Partnership and Filing with Health Canada for Additional Evolve Dry Eye Product

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company announced today that it has expanded its partnership with Medicom Healthcare (“Medicom”) to include an additional formulation in...

Sep 14, 2020 12:51 pm ET

Aequus Announces Filing of New Medical Device License for Evolve Dry Eye Products in Canada

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company announced today that it has submitted New Medical Device License (“MDL”) applications for two dry eye products in the Evolve®...

Aug 31, 2020 08:30 am ET

Aequus Prepares for Health Canada Regulatory Filing as Partner Receives MDSAP Certificate for Dry Eye Products

Aug 27, 2020 09:30 pm ET

Aequus Provides General Update and Second Quarter 2020 Financial Highlights

Aug 26, 2020 08:15 am ET

Aequus Announces Issuance of Stock Options

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today a grant of 1,000,000 stock options...

Aug 20, 2020 08:30 am ET

Aequus Announces New Chief Commercial Officer

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to welcome Grant Larsen to the Aequus...

Aug 06, 2020 11:08 am ET

Aequus Completes C$2.5 million Equity Financing

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

Jul 28, 2020 08:22 am ET

Aequus Announces "Best Efforts" Public Offering

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

Jun 04, 2020 10:30 pm ET

Aequus Announces Issuance of Stock Options

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today a grant of 1,124,337 stock options...

Jun 01, 2020 03:13 pm ET

Amendment on Earlier Release: Aequus Provides General Update and First Quarter 2020 Financial Highlights

Jun 01, 2020 09:15 am ET

Aequus Provides General Update and First Quarter 2020 Financial Highlights

Apr 29, 2020 09:00 pm ET

Aequus Provides General Update and 2019 Financial Highlights

Apr 21, 2020 11:00 am ET

Aequus Announces Positive Update on Dry Eye Product Launch Plans

Mar 23, 2020 08:45 am ET

A Message from the CEO of Aequus Pharmaceuticals

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today a message from the CEO and Chairman...

Feb 19, 2020 09:20 am ET

Aequus Announces Appointment of New Director to its Board & Stock Option Grant

Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced that, further to its news release on...

Feb 03, 2020 09:15 am ET

Aequus and Medicom Announce Changes to their Respective Commercial Leadership Teams

Jan 16, 2020 09:15 am ET

Aequus Receives Positive Formulary Decision in British Columbia for Specialty Portfolio Product

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that a major health authority...

Jan 10, 2020 09:15 am ET

Aequus to Broaden Vistitan Reimbursement for Patients in Canada

Dec 13, 2019 10:45 am ET

Aequus and Medicom Healthcare Sign Exclusive Term Sheet To Jointly Advance Ophthalmology Products Into The USA

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce the signing of a term sheet...

Nov 29, 2019 04:30 pm ET

Aequus Provides Third Quarter 2019 Financial Highlights

Oct 18, 2019 08:30 am ET

Aequus Highlights Study Indicating Vistitan as the Most Effective Treatment for Glaucoma

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) today acknowledged the research results presented at the American Academy of Ophthalmology in San Francisco that revealed bimatoprost 0.03%, branded as PrVistitanTM...

Sep 17, 2019 08:45 am ET

Aequus Replaces Expired Short Form Base Shelf Prospectus

Aequus Pharmaceuticals Inc. (TSX-V : AQS, OTCQB : AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that, further to its press release...

Aug 27, 2019 09:15 am ET

A Return to Revenue Growth - Aequus Provides Second Quarter 2019 Financial Highlights

Jul 29, 2019 08:30 am ET

Aequus Signs Exclusive Distribution Agreement with Medicom Healthcare for Canadian Distribution Rights of Ophthalmic Products

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce the signing of an exclusive distribution agreement with Medicom Healthcare Ltd. (“Medicom”), a United Kingdom based pharmaceutical company...

May 30, 2019 08:00 pm ET

Aequus Provides First Quarter 2019 Financial Highlights

May 30, 2019 07:30 pm ET

Aequus to Clarify Press Release of 23rd May 2019 Relating to Zepto Capsulotomy System and Kensington Eye Institute

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) confirms its release of 23rd May 2019. Aequus is pleased to be a supplier of the Zepto Capsulotomy System (“the Product”) with the Kensington Eye Institute in...

May 23, 2019 08:45 am ET

Aequus to supply Kensington Eye Institute with Zepto Capsulotomy system; Extends Distribution Agreement with Mynosys

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce an agreement for the Zepto Precision Pulse Capsulotomy device (“Zepto”) with The Kensington Eye Institute, a world renowned clinic and leader...

May 02, 2019 09:15 am ET

Aequus Closes $2.35 Million Offering of Convertible Debenture Units

Aequus Pharmaceuticals Inc. (“Aequus” or the “Company”) (TSX-V: AQS) (OTCQB:AQSZF) is pleased to announce that it has closed its previously announced offering (the “Offering”) of convertible debenture units of the Company (the “Convertible...

Apr 30, 2019 10:00 am ET

Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference on May 1, 2019

Apr 26, 2019 09:16 am ET

Aequus Announces Filing of Prospectus Supplement and an Update to Previously Announced Public Offering of Convertible Debenture Units

Aequus Pharmaceuticals Inc. (the “Company”) (TSX-V: AQS) (OTCQB:AQSZF) is pleased to announce that it has filed a prospectus supplement (the “Prospectus Supplement”) to its short form base shelf prospectus dated August 15, 2017 (the “Base Shelf...

Apr 24, 2019 11:36 pm ET

Aequus Provides Financial Year End Financial Highlights

Apr 03, 2019 10:36 am ET

IIROC Trading Resumption - AQS

VANCOUVER, April 3, 2019 /CNW/ - Trading resumes in:

Apr 03, 2019 10:22 am ET

Aequus Announces Public Offering of Convertible Debenture Units

Aequus Pharmaceuticals Inc. (the “Company”) (TSX-V: AQS) (OTCQB:AQSZF) is pleased to announce that it expects to file a preliminary prospectus supplement (the “Prospectus Supplement”) to its short form base shelf prospectus dated August 15, 2017...

Apr 03, 2019 09:34 am ET

IIROC Trading Halt - AQS

VANCOUVER, April 3, 2019 /CNW/ - The following issues have been halted by IIROC:

Mar 07, 2019 08:30 am ET

Aequus Signs Term Sheet for Five Preservative Free Dry Eye Products

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce the signing of a term sheet for an exclusive license with Medicom Healthcare Ltd. (“Medicom”), a United Kingdom based pharmaceutical company...

Dec 17, 2018 08:30 am ET

Aequus Signs Term Sheet with European Partner for a Preservative Free Therapeutic in Ophthalmology

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce the signing of a term sheet for an exclusive license in Canada of an undisclosed preservative free ophthalmic therapeutic with a European...

Nov 29, 2018 06:15 pm ET

Aequus Reports Largest Quarterly Revenue in Company History and Provides Management Update

Nov 15, 2018 08:45 am ET

Aequus Strengthens Clinical Experience on Strategic Advisory Board in Ophthalmology, and Adds Commercial and Regulatory Expertise

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce the addition of Dr. Vikram...

Nov 13, 2018 08:45 am ET

Aequus Hosts Live Webinar Demonstrating the Zepto® Capsulotomy System, Led by Dr. Ike Ahmed

Nov 05, 2018 08:45 am ET

Aequus forms Strategic Advisory Board in Ophthalmology, Chaired by Dr. Ike Ahmed

Aug 27, 2018 08:45 am ET

Aequus Reports 5th Consecutive Quarter of Revenue Growth

Aug 10, 2018 08:45 am ET

Aequus Closes Balance of $775,000 Equity Financing

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing,...

Aug 09, 2018 08:45 am ET

Aequus Announces Fully-subscribed $775,000 Equity Financing

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it intends to complete a...

Jul 31, 2018 08:45 am ET

Aequus Announces Closing of $800,000 Equity Financing

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that, further to its news...

Jul 24, 2018 06:00 pm ET

Issuance of Stock Options

Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), Aequus is pleased to announce it has granted incentive stock options to Damien King, a new director of the Company for the right to purchase up to an aggregate of...

Jul 23, 2018 08:45 am ET

Aequus Announces Proposed $800,000 Equity Financing To Next Edge Biotech Plus Fund

Jul 19, 2018 08:45 am ET

Aequus Announces Expansion of Market Opportunity for its Long Acting Anti-Nausea Transdermal Patch

Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”) is pleased to announce a recent expansion of the market opportunity for its reformulated anti-nausea transdermal patch, AQS1303, into the European market. Diclectin®,...

Jul 16, 2018 08:45 am ET

Aequus Extends and Enhances Commercial Agreement to Promote Vistitan in Canada

Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), is pleased to announce that it has agreed to new terms for its promotional service agreement with Sandoz on PRVistitan™ (“Vistitan”) with improved economics and a...

Jul 13, 2018 08:45 am ET

Aequus Announces New Independent Director to its Board

Jun 21, 2018 08:45 am ET

Aequus and Corium Join Forces to Advance Anti-Nausea Transdermal Patch

Jun 18, 2018 08:45 am ET

Aequus Announces First Canadian Cataract Procedures Using Zepto Capsulotomy System

Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), is pleased to announce the first four cataract procedures in Canada using the Zepto® Capsulotomy System (“Zepto”), a precision pulse capsulotomy device, have been...

May 31, 2018 08:45 am ET

Aequus Provides First Quarter 2018 Financial and Corporate Highlights

May 16, 2018 08:45 am ET

Aequus Announces Official Launch of Zepto Capsulotomy System in Canada to be June 1, 2018

Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), is pleased to announce it will be formally launching the Zepto® Precision Pulse Capsulotomy System (“Zepto”) in Canada on June 1, 2018 during the Canadian...

May 03, 2018 08:45 am ET

Aequus Receives Positive FDA Regulatory Guidance for Anti-Nausea Patch

Apr 27, 2018 09:30 am ET

Aequus Provides Fourth Quarter and Fiscal 2017 Financial Highlights, Third Consecutive Quarter of Revenue Growth

VANCOUVER, British Columbia, April 27, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the...

Apr 26, 2018 12:00 pm ET

Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference on May 2, 2018

VANCOUVER, British Columbia, April 26, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced that its Chairman and...

Apr 17, 2018 08:45 am ET

Aequus and Camargo Complete Pre-Investigational New Drug Submission with FDA for Transdermal Anti-Nausea Program

VANCOUVER, British Columbia, April 17, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has issued...

Apr 12, 2018 08:45 am ET

Aequus Adds Zepto Capsulotomy System, A Revenue Generating Product, to Commercial Ophthalmology Portfolio

VANCOUVER, B.C., April 12, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), is pleased to announce it has entered into a commercial agreement with Mynosys Cellular Devices, an ophthalmology focused medical device company...

Mar 19, 2018 08:45 am ET

Aequus Expands Market in Quebec for Tacrolimus IR

First-to-market generic tacrolimus will be included on Sigma Santé contract as of May 2018, building on continued commercial success of Aequus’ promotional arm

Mar 07, 2018 08:45 am ET

FDA Confirms Date to Providing Regulatory Guidance for Aequus’ Anti-Nausea Patch

VANCOUVER, British Columbia, March 07, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the Company has...

Mar 05, 2018 08:45 am ET

Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

Ehave’s Bioinformatics Platform Technology to Be Used to Evaluate Aequus’ Products in Multiple Neurological Disorders

Mar 05, 2018 08:06 am ET

Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

Ehave's Bioinformatics Platform Technology to Be Used to Evaluate Aequus' Products in Multiple Neurological Disorders

Mar 05, 2018 07:45 am ET

Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

VANCOUVER, British Columbia, March 5, 2018 /PRNewswire/ --

Jan 31, 2018 06:21 pm ET

Aequus Announces Closing of $300,000 Equity Financing

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICESAequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

Jan 31, 2018 08:00 am ET

Aequus and Camargo Prepare for Meeting with FDA to Advance Anti-Nausea Patch

Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced plans to advance its...

Jan 25, 2018 05:27 pm ET

Aequus Announces Change to Proposed $300,000 Equity Financing

Jan 11, 2018 08:30 am ET

Aequus Announces Proposed $300,000 Equity Financing

Jan 11, 2018 05:00 am ET

CannaRoyalty and Aequus Pharmaceuticals Announce Joint Venture to Develop and Commercialize Cannabis-Based Therapies Targeting Neurological Disorders

CannaRoyalty to contribute Bodhi Research position into the JV in exchange for equity

Jan 11, 2018 05:00 am ET

CannaRoyalty and Aequus Pharmaceuticals Announce Joint Venture to Develop and Commercialize Cannabis-Based Therapies Targeting Neurological Disorders

CannaRoyalty to contribute Bodhi Research position into the JV in exchange for equity

Dec 08, 2017 08:04 pm ET

Aequus announces the issuance of stock options

Nov 29, 2017 04:15 pm ET

Aequus Provides Third Quarter 2017 Operational Highlights

Nov 16, 2017 09:43 am ET

Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole

Sep 28, 2017 09:30 am ET

Ehave Highlights Recent Developments and Corporate Strategy in Updated Letter to Shareholders

TORONTO, Sept. 28, 2017 /CNW/ -- Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced publication of a new CEO letter to the Company's shareholders, providing an update on corporate developments and business strategy. As outlined in the letter, Ehave has established and is executing on key partnerships that allow the company to generate revenue while demonstrating its utility for mental health researchers, pharmaceutical companies and clinicians, setting Ehave on a strong growth trajectory

Sep 28, 2017 09:30 am ET

Ehave Highlights Recent Developments and Corporate Strategy in Updated Letter to Shareholders

TORONTO, Sept. 28, 2017 /PRNewswire/ -- Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced publication of a new CEO letter to the Company's shareholders, providing an update on corporate developments and business strategy. As outlined in the letter, Ehave has established and is executing on key partnerships that allow the company to generate revenue while demonstrating its utility for mental health researchers, pharmaceutical companies and clinicians, setting Ehave on a strong growth tra

Sep 07, 2017 01:23 pm ET

Aequus Announces Positive Results for Proof of Concept Clinical Trial of Anti-Nausea Patch

Aug 29, 2017 04:30 pm ET

Aequus Provides Second Quarter 2017 Operational Highlights

Aug 28, 2017 09:00 am ET

Aequus and Ehave Collaborate on Bioinformatics Platform for Management of Clinical Trials

Aug 24, 2017 09:00 am ET

Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole

Aug 16, 2017 02:29 pm ET

Aequus Receives Approval for Short Form Base Shelf Prospectus to Raise up to C$20,000,000

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

Aug 01, 2017 09:00 am ET

Aequus and Scientus Agree to Terms for a Medical Cannabis Commercial Supply and Product Development Collaboration

Aequus Pharmaceuticals Inc., ("Aequus") (TSX VENTURE: AQS) (OTCQB: AQSZF), a specialty life sciences company focused on providing patients with differentiated and enhanced delivery systems for existing and approved drugs, and Scientus Pharma Inc.,...

Jul 05, 2017 09:00 am ET

Aequus Receives Approval from Health Canada to Initiate Proof of Concept Clinical Trial of Anti-Nausea Patch

Jun 15, 2017 09:00 am ET

Aequus Advances Clinical Development of Transdermal Anti-Nausea Patch

Jun 13, 2017 10:52 am ET

IIROC Trading Resumption - AQS

VANCOUVER, June 13, 2017 /CNW/ - Trading resumes in:

Jun 13, 2017 09:46 am ET

IIROC Trading Halt - AQS

VANCOUVER, June 13, 2017 /CNW/ - The following issues have been halted by IIROC:

Jun 13, 2017 09:00 am ET

Santen and Aequus Enter Into a Commercial Collaboration in Canada

Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), today announced that it has entered into an exclusive agreement in Canada with Santen Incorporated, the Canadian Branch ("Santen"), a subsidiary of Santen...

Jun 12, 2017 10:00 pm ET

Aequus Approves Advance Notice Policy

Jun 01, 2017 09:00 am ET

Aequus Pharmaceuticals and CDRD Announce Research Collaboration to Improve Cannabinoid-Based Therapeutics

Today Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus") a specialty pharmaceutical company with expertise in drug delivery and clinical development, and the Centre For Drug Research and Development ("CDRD"), Canada's national...

May 30, 2017 12:35 pm ET

Aequus Provides First Quarter 2017 Financial Highlights

May 15, 2017 02:35 pm ET

Aequus Validates Need for Improved Delivery Methods of Medical Cannabis

May 01, 2017 03:50 pm ET

Aequus Provides Fourth Quarter and Fiscal 2016 Financial Highlights

Apr 24, 2017 09:30 am ET

Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference

Apr 05, 2017 09:00 am ET

Aequus Launches Medical Cannabis Physician Research in US and Canada

Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus") announced today they will fund market research targeting up to 500 physicians across Canada and certain US states to further understand their current prescribing experience and...

Apr 03, 2017 05:30 am ET

Aequus Announces Positive Results from Second Proof of Concept Study for Long-Acting Aripiprazole Transdermal Patch

Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), today announced results from its second Proof of Concept study designed to evaluate the pharmacokinetics (PK), safety and tolerability following repeat...

Mar 13, 2017 09:12 am ET

Aequus Raises $5.2 Million Through Bought Deal Financing Including Full Exercise of the Over-Allotment Option

Mar 03, 2017 10:08 am ET

IIROC Trading Resumption - AQS

VANCOUVER, March 3, 2017 /CNW/ - Trading resumes in:

Mar 03, 2017 09:40 am ET

Aequus Announces Upsizing of Previously Announced Bought Deal of Units to $4.5 Million

/NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/

Mar 03, 2017 09:22 am ET

IIROC Trading Halt - AQS

VANCOUVER, March 3, 2017 /CNW/ - The following issues have been halted by IIROC:

Mar 02, 2017 04:28 pm ET

Aequus Announces $3 Million Bought Deal Financing

/NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/

Mar 02, 2017 08:00 am ET

Aequus Licenses Rights to Cannabinoid Transdermal Patch to Treat Neurological Disorders

Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company") announced today that through a previously announced Research Service Contract with Transdermal Research Pharma Lab ("TRPL") it has entered into a binding term...

Feb 14, 2017 08:00 am ET

Aequus Successfully Completes Dosing in Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch

Feb 01, 2017 09:00 am ET

Aequus Receives Non-Dilutive Funding from the Government of Canada to Support Aripiprazole Patch Development

Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), today announced funding of up to CAD$100,000 from the National Research Council of Canada Industrial Research Assistance Program ("NRC-IRAP") to support the...

Jan 09, 2017 09:00 am ET

Aequus Initiates Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch

Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), announced today that it has received approval from Health Canada to initiate a multi-dose Proof of Concept clinical trial to evaluate the bioavailability and...

Dec 01, 2016 08:00 am ET

Aequus Obtains Public Reimbursement for Vistitan in Two Additional Provinces: Alberta and Manitoba

Nov 30, 2016 08:00 am ET

Aequus Provides Q3 2016 Financial Highlights With Substantial Increase in Quarter Over Quarter Revenues

Nov 17, 2016 09:00 am ET

Aequus Prepares for Proof of Concept Clinical Study for Transdermal Anti-Nausea Diclegis Program

Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company") announced today that is has entered into a service agreement with Corium International, Inc. (NASDAQ: CORI) for the manufacturing of clinical trial materials...

Oct 17, 2016 09:00 am ET

Aequus Advances Clinical Development of Transdermal Aripiprazole Patch

Oct 03, 2016 12:37 pm ET

Aequus Partners With Camargo to Support US Regulatory Strategy for Development Programs

Sep 29, 2016 08:00 am ET

Aequus Obtains Ontario Provincial Listing for Vistitan(TM)

Sep 13, 2016 09:19 am ET

Aequus Closes Financing for Gross Proceeds of C$2,743,920

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Aequus Pharmaceuticals Inc. (TSX VENTURE:AQS)(OTCQB:AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus...

Sep 06, 2016 07:58 am ET

Aequus Pharmaceuticals Inc. Announces $2.0 to $4.0 Million Best Efforts Financing

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Aequus Pharmaceuticals Inc. (TSX VENTURE:AQS) (OTCQB:AQSZF) (the "Company" or "Aequus") is pleased to announce that it has entered into an...

Aug 30, 2016 08:30 am ET

Aequus Provides Corporate Update on Commercial and Development Programs

Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) 2016 YTD Company Highlights: Aequus reported its first commercial revenues in Q1 of 2016 for promotional activities in the Canadian market. Second-quarter 2016 revenues of $118,100 and...

Aug 05, 2016 11:00 am ET

Aequus Announces Advancement of Anti-Nausea Transdermal Extended-Release Patent Application

Jul 29, 2016 09:57 am ET

Aequus Announces Advancement of Clobazam Transdermal Patent Application

Jul 22, 2016 05:30 pm ET

Aequus Appoints Ann Fehr as Chief Financial Officer

Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or "Company") today announced Ann Fehr is joining the growing specialty pharmaceutical company as its new Chief Financial Officer (CFO) effective July 22, 2016. Ms. Fehr brings...

May 02, 2016 09:00 pm ET

Ad blocking detected

Aequus Pharmaceuticals Inc. (V:AQS)

Business Focus: Pharmaceuticals (NEC)